Research graph
References from Development of bi-functional hybrid IgGA antibodies for enhancing cancer immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
IgA and FcαRI: pathological roles and therapeutic opportunities
10.3389/fimmu.2019.00553 · 2019 · External reference
IgA antibodies for cancer therapy
10.1016/s1040-8428(01)00105-6 · 2001 · External reference
Serum IgA Fc effector functions in infectious disease and cancer
10.1111/imcb.12306 · 2020 · External reference
Fcγ receptors and immunomodulatory antibodies in cancer
10.1038/s41568-023-00637-8 · 2024 · External reference
FcγR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy
10.3389/fimmu.2019.00292 · 2019 · External reference
Correlation of anti-HLA IgA alloantibodies and Fc receptor motives with kidney allograft survival
10.3390/immuno2020023 · 2022 · External reference
Potent fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG
10.3389/fimmu.2019.00704 · 2019 · External reference
Neutrophils kill antibody-opsonized cancer cells by trogoptosis
10.1016/j.celrep.2018.05.082 · 2018 · External reference
IgA Fc receptor I signals apoptosis through the FcR ITAM and affects tumor growth
10.1182/blood-2006-06-025882 · 2007 · External reference
The neutrophil: the underdog that packs a punch in the fight against cancer
10.3390/ijms21217820 · 2020 · External reference
IgA complexes induce neutrophil extracellular trap formation more potently than IgG complexes
10.3389/fimmu.2021.761816 · 2022 · External reference
Neutrophils as immune effector cells in antibody therapy in cancer
10.1111/imr.13159 · 2023 · External reference
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
10.1084/jem.20100643 · 2010 · External reference
The basic principles of chimeric antigen receptor design
10.1158/2159-8290.cd-12-0548 · 2013 · External reference
Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression
2025 · External reference
PD-L1 expression in human cancers and its association with clinical outcomes
2016 · External reference
Neoadjuvant checkpoint blockade for cancer immunotherapy
2020 · External reference
Regulatory mechanisms of PD-1/PD-L1 in cancers
10.1186/s12943-024-02023-w · 2024 · External reference
A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein-protein interactions by fluorescence polarization
10.1021/bi048233g · 2004 · External reference
IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions
10.1016/j.chembiol.2014.10.017 · 2014 · External reference
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
10.1038/nature14011 · 2014 · External reference
PD-1/PD-L1 inhibitors response in triple-negative breast cancer: can long noncoding RNAs be associated?
10.3390/cancers15194682 · 2023 · External reference
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
2018 · External reference
